drugset / Trial / NCT01012310

Group Study To Investigate The Safety, Toleration And Pharmacokinetics Of Multiple Oral Doses Of PF-04531083 In Healthy Subjects

NCT01012310

Phase 1 Completed 40 enrolled Pfizer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the safety and toleration of single and multiple doses of PF-04531083. (To investigate the plasma and urinary pharmacokinetics of PF-04531083 and its metabolites, following single and multiple dose administration in healthy male and/or female subjects; and to determine whether PF-04531083 raises levels of enzymes involved in metabolism of other drugs following multiple dosing).

Timeline

Start
2009-11
Primary completion
2010-02
Completion
2010-04

Drugs

EvaluationDrugModalityDoseRoute
Subject PF-04531083 Small molecule 100 mg Oral
Subject PF-04531083 Small molecule 300 mg Oral
Subject PF-04531083 Small molecule 500 mg Oral

Indications

No indication recorded.